Results 21 to 30 of about 16,465 (200)
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
, 2022 Supplementary Figure from Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ...
Jun Zhang (48506) +15 more
core +5 more sources
Off-label uses of TNFa inhibitors and IL12/23 inhibitors in dermatology [PDF]
, 2021 TNFa inhibitors, which include adalimumab, infliximab, etanercept, certolizumab, and golimumab, and IL12/23 inhibitor, ustekinumab, have been widely used as a U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis.
Hong, Julie J +12 more
core +1 more source
PLoS ONE, 2021 Systemic interleukin-12 (IL12) anti-tumor therapy is highly potent but has had limited utility in the clinic due to severe toxicity. Here, we present two IL12-expressing vector platforms, both of which can overcome the deficiencies of previous systemic ...
Jardin A Leleux +7 more
doaj +1 more source
, 2022 Supplementary Figure from Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for ...
Zhiliang Jia (15043340) +10 more
core +2 more sources
Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. [PDF]
PLoS ONE, 2012 Both adoptive immunotherapy and gene therapy hold a great promise for treatment of malignancies. However, these strategies exhibit limited anti-tumor activity, when they are used alone.
Zhi Yang +12 more
doaj +1 more source
Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12 [PDF]
Molecular Cancer Therapeutics, 2021 Abstract The promise of IL12 as a cancer treatment has yet to be fulfilled with multiple tested approaches being limited by unwanted systemic exposure and unpredictable pharmacology. To address these limitations, we generated exoIL12, a novel, engineered exosome therapeutic that displays functional IL12 on the surface of an exosome ...
Nuruddeen D. Lewis +19 more
openaire +2 more sources
Nature Communications, 2021 The immunocytokine NHS-IL12 is targeted to necrotic tumour areas to prompt an immune response. Authors show here in mouse colon and breast models that the combination of histone deacetylase inhibitor, Entinostat, and NHS-IL12 generates a tumour ...
Kristin C. Hicks +9 more
doaj +1 more source
Zanco Journal of Pure and Applied Sciences, 2022 Background: Interleukins have a substantial role in the improvement of many types of cancer. Interleukin genes have many single nucleotide polymorphisms (SNPs) that may alter protein synthesis or function, and many of them have been related to cancer ...
Zhian Ismael A. Daham +1 more
doaj +1 more source
Cancer Cell International, 2020 Background Oncolytic viruses have emerged as an alternative therapeutic modality for cancer as they can replicate specifically in tumour cells and induce toxic effects leading to apoptosis.
Syed Umar Faruq Syed Najmuddin +10 more
doaj +1 more source